Overview

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

Status:
Completed
Trial end date:
2016-06-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of intramuscular homologous and heterologous prime-boost regimens of Ad35.RSV.FA2 (human adenovirus-vectored vaccine candidate) and Ad26.RSV.FA2 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Crucell Holland BV